Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT03322384 | UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 20 | University of California, DavisOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04679038 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 222 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05167370 | High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors | terminated | Phase 2 | 2 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | completed | Phase 1 / Phase 2 | 176 | Incyte CorporationINDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03220854 | SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx | completed | Phase 2 | 5 | Virginia Commonwealth UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | unknown | Phase 2 | 180 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT02587598 | Study of INCB053914 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 97 | Incyte CorporationINDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Nov 18, 2021 | clinicaltrials |
| NCT05119933 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | unknown | Phase 1 / Phase 2 | 55 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05115500 | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) | unknown | Phase 2 | 55 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT05097781 | Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients | unknown | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00049361 | Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases | completed | Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02423343 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2021 | clinicaltrials |
| NCT05028478 | A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 164 | Curon Biopharmaceutical (Australia) Co Pty LtdINDUSTRY | 0 | Aug 31, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors(NKTR-214) | completed | Phase 1 / Phase 2 | 28 | Nektar TherapeuticsINDUSTRY | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04180384 | A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients | completed | Phase 2 | 44 | Athenex, Inc.INDUSTRY | 4 | Jul 29, 2021 | clinicaltrials |
| NCT02765165 | Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 26 | Proximagen, LLCINDUSTRY | 2 | Jul 23, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | completed | Phase 2 | 27 | Nektar TherapeuticsINDUSTRY | 2 | Jul 12, 2021 | clinicaltrials |
| NCT04237805 | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 1 / Phase 2 | 280 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04937842 | Microtransplantation for Advanced and Relapsed Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04337463 | ATG-008 Combined With Toripalimab in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Sichuan UniversityOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT04869475 | Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation | unknown | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03264066 | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | completed | Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 6 | May 11, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT02281409 | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT03017521 | K-BASKET, TAS-117, PI3K/AKT Gene Aberration | completed | Phase 2 | 13 | Yonsei UniversityOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01002924 | Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) | completed | Phase 2 | 1 | EndocyteINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04832204 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | unknown | Phase 2 | 20 | Beijing HospitalOTHER_GOV | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01981187 | LGX818 for Patients With BRAFV600 Mutated Tumors(SIGNATURE) | terminated | Phase 2 | 12 | PfizerINDUSTRY | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01178411 | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | completed | Phase 1 / Phase 2 | 60 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03600467 | Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma(START) | terminated | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT03704246 | Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors | unknown | Phase 2 | 123 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Mar 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2022source: clinicaltrials